Answers are grounded in this paper and cite their sources.
Background/Objectives: Depression is a clinically relevant neuropsychiatric manifestation of Sjögren’s disease, although the underlying mechanisms remain incompletely understood. Autoimmune and neuroinflammatory processes, including the potential role of autoantibodies, may contribute to its development. This study aimed to investigate the association between anti-Ro antibodies, with particular emphasis on anti-Ro52, and the presence of depression in patients with Sjögren’s disease and to explore whether quantitative anti-Ro52 antibody levels may provide patient-level information relevant to a more personalized assessment of neuropsychiatric manifestations. Methods: This retrospective, observational, cross-sectional study included 141 adult patients with Sjögren’s disease treated at the University Hospital of Split between 2020 and 2023. Depression was defined as a documented diagnosis supported by psychiatric evaluation. The association between anti-Ro52 antibody concentration and depression was assessed using Firth’s penalized logistic regression, adjusted for age and sex, with correction for multiple testing using the false discovery rate procedure. A sensitivity analysis was performed after restricting the analysis to patients with primary Sjögren’s disease. Results: Depression was documented in 16/141 patients (11.3%). Anti-Ro52 concentrations were available for 111 patients, including 13 with depression. Higher anti-Ro52 concentrations were significantly associated with lower odds of depression. A one-standard-deviation increase in anti-Ro52 concentration was associated with 70% lower odds of depression (OR 0.30; 95% CI 0.12–0.61; p < 0.001). The association remained significant after multiple-testing correction (overall FDR-adjusted p = 0.046). The inverse association remained significant in the sensitivity analysis restricted to patients with primary Sjögren’s disease (OR per 1-SD increase = 0.38; 95% CI 0.14–0.82; p = 0.013). Conclusions: Higher anti-Ro52 antibody concentrations were associated with lower odds of documented depression in patients with Sjögren’s disease after adjustment for age and sex. These findings suggest that quantitative serological profiling may provide patient-level information relevant to a more personalized assessment of neuropsychiatric manifestations. However, prospective studies using standardized depression assessments are required to determine the clinical relevance and potential utility of anti-Ro52 levels in individualized patients.
No takes yet. Share an insight, caveat, or question.
Lerotić et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: